Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 3/5 criteria met.
- ✅ Price trend passed
- ⚠️ Mixed growth
- ✅ Debt passed
- ❌ P/E failed
- ✅ Correction passed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2019 → 2020: 140.61%
Price change 2020 → 2021: 216.24%
Price change 2021 → 2022: -41.73%
Price change 2022 → 2023: -29.74%
Price change 2023 → 2024: 7.97%
Price change 2024 → 2025: -16.45%
Price change 2025 → 2026: 7.09%
Price change 2026 (year to date): 5.44%
Financial growth
Revenue CAGR (8 years): 55.12%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 0.01
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -12.57
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 12.54% from the high over 6 months.
Correction between 10.0% and 20.0% (target range).
Criteria of the Investlytic model
- / 5Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| BioNTech SE | – | 0.01 | +60.8 % | 🔒 |
| Sartorius Stedim Biotech S.A. | 47.5 | 0.64 | +13.7 % | – |
| bioMérieux S.A. | 22.5 | 0.11 | +7.6 % | – |
| Moderna, Inc. | – | 0.22 | +37.8 % | – |
| EssilorLuxottica S.A. | 33.6 | 0.37 | +14.2 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|